Clinical trial · Observational
Registry of the German CLL Study Group
Registry of the German CLL Study Group Long Term Follow-up of Patients With CLL, B-PLL, T-PLL, SLL,T or NK-LGL, HCL and Richter's Transformation
NCT02863692CI-TRIAL-00098588CLL-RegistryrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma (SLL), T/Natural Killer large granular lymphocyte leukemia (T or NK-LGL), Hairy cell leukemia (HCL) and Richter's transformation
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CLL | Chronic Lymphocytic Leukemia | ALIAS | 0.90 |
| HCL | Hairy Cell Leukemia | ALIAS | 0.90 |
| Leukemia, Prolymphocytic, B-Cell | Leukemia | ONTOLOGY_EXACT | 0.85 |
| Leukemia, Prolymphocytic, T-Cell | Leukemia | ONTOLOGY_EXACT | 0.85 |
| NK-LGL Leukemia | Chronic Lymphoproliferative Disorder of NK-Cells | ALIAS | 0.90 |
| Richter´s Transformation | — | UNRESOLVED | — |
| SLL | Small Lymphocytic Lymphoma | ALIAS | 0.90 |
| T-LGL Leukemia | T-Cell Large Granular Lymphocyte Leukemia | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- from date of registry entry until date of death, up to 12 years
- description
- Overall survival will be measured from date of registry entry until date of death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria (all must apply) 1. Confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK-LGL, HCL or Richter's transformation 2. 18 years of age or older 3. Signed, written informed consent 4. Presence of one or more of the following disease situations: * Newly diagnosed patients without treatment indication (eligible for watch and wait Approach Treatment within a clinical trial according to the AMG or status post participation in a clinical Trial) * Treatment with standard therapies approved for the eligible entities or status post treatment (outside of clinical trials) * Referral for evaluation the indication for HSCT * Relapsed disease status (even if first diagnosis was prior to activation of the registry) Exclusion Criteria 1. Patients without confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK- LGL, HCL or Richter's transformation 2. Cerebral dysfunction, legal incapacity
References
Publications (3)
- BACKGROUNDKutsch N, Giza A, Robrecht S, Stumpf J, Federhen A, Stoltefuss A, Vehling-Kaiser U, Koenigsmann M, Tausch E, Schneider C, Stilgenbauer S, Illmer T, Schlag R, Dorfel S, Gaska T, Kiehl M, Muller-Hagen S, Moorahrend E, Linde H, Schlenska-Lange A, von Tresckow J, Fischer K, Eichhorst B, Hallek M, Fink AM. Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry. Eur J Haematol. 2024 Aug;113(2):235-241. doi: 10.1111/ejh.14220. Epub 2024 May 1. PMID 38693677
- BACKGROUNDFurstenau M, Giza A, Stumpf T, Robrecht S, Maurer C, Linde H, Jacobasch L, Dorfel S, Aldaoud A, von Tresckow J, Koenigsmann M, Gaska T, Kaiser U, Harich HD, Fischer K, Eichhorst B, Hallek M, Fink AM. Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. Am J Hematol. 2021 Dec 1;96(12):E457-E460. doi: 10.1002/ajh.26363. Epub 2021 Oct 8. No abstract available. PMID 34591989
- DERIVEDvon Tresckow J, Heyl N, Robrecht S, Giza A, Aldaoud A, Schlag R, Klausmann M, Linde H, Stein W, Schwarzer A, Fischer K, Cramer P, Eichhorst B, Hallek M, Fink AM. Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group. Ann Hematol. 2023 Nov;102(11):3083-3090. doi: 10.1007/s00277-023-05314-2. Epub 2023 Jun 26. PMID 37358640